Products
Online Inquiry
Regorafénib N-oxyde (M2)
Cat. No.:
0225LY-0767
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
Regorafenib N-oxide M2 is an active metabolite of Regorafenib that inhibits multiple targets, including Raf-1, Kit, RET, PDGFR-beta, and VEGFR1/2/3, with high potency.
Synonym:
835621-11-9; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-2-(methylcarbamoyl)pyridine 1-oxide; Regorafenib (Pyridine)-N-oxide; Regorafenib metabolite M2; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methyl-1-oxidopyridin-1-ium-2-carboxamide; 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)-3-fluorophenoxy)-N-methyl-, 1-oxide
CAS No.:
835621-11-9
Compound CID:
53491674
Formula:
C21H15ClF4N4O4
Formula Weight:
498.81
Specification
Targets&IC50:
VEGFR1: 13nM ; RET: 22nM ; VEGFR3: 46nM ; c-Kit: 7nM ; Raf-1: 2.5 nM ; PDGFRβ: 1.5nM ; VEGFR2: 4.2nM
Relative Density:
1.49 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Regorafenib N-oxide (M2) can be used in pharmacokinetic studies to evaluate the activity and metabolic profile of the parent compound regorafenib.
Library Information
Target:
c-Kit; PDGFR; Raf; VEGFR; c-RET
Receptor:
Kit; PDGFRβ; Raf-1; RET; VEGFR1; VEGFR2; VEGFR3
Pathways:
MAPK; Angiogenesis; Apoptosis; Tyrosine kinase/adaptors; Metabolism
Plate Number:
AOCL-10
Plate Location:
h5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
5.67 mg/mL; 11.37 mM
